**Supplementary table 1**. Search strategy for Pub Med.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Search term** | | **PubMed results** | |
|  | Systematic review about the use of histology as an endpoint in UC trials |  | | |
| 1 | Ulcerative colitis | | 46 341 | |
| 2 | Histological healing OR histological remission OR histological improvement | | 20 532 | |
| 3 | Infliximab OR adalimumab OR Golimumab OR Certolizumab OR Vedolizumab OR Ustekinumab OR tofacitinib OR Etrolizumab OR Etrasimod OR Ozanimod OR Upadacitinib | | 20 676 | |
|  | 1+2+3 | | 32 | |
|  | Systematic review about the impact of histological remission on disease outcomes | | |  |
| 4 | Outcomes OR hospitalization OR relapse | | 1 593 687 | |
|  | 1+2+4 | | 117 | |
| 5 | neoplasia OR dysplasia OR cancer | | 3 961 845 | |
|  | 1+2+5 | | 41 | |